<prompt> True about zafirlukast is :It inhibit lipooxygenase pathwayIt blocks LT receptorIt can be administered orallyAll of these  <response>: Zafirlukast and montelukast are cysteinyl leukotriene receptor antagonists. They cause modest improvement in lung function and reduction in asthma symptoms and lessen the need for beta-agonist rescue therapy. These drugs can be considered as alternatives to low-dose inhaled corticosteroids in patients with persistent asthma.Zafirlukast is long-acting and can be given twice to once daily orally. It is a modest bronchodilator that reduces asthma morbidity, provides protection against exercise-induced asthma and diminishes nocturnal symptoms.These are less effective than corticosteroids. 